Tioga Pharmaceuticals is focused on the development of novel therapies for
the treatment of gastrointestinal diseases. Tioga was founded in 2005 by Forward Ventures and raised $24 million in its Series A financing, with New Leaf Venture Partners and BB Biotech Ventures also investing in the round.
Tioga's lead compound, asimadoline, is currently in Phase 3 clinical development for the treatment of irritable bowel syndrome (IBS). This disorder represents a large unmet medical need and substantial market opportunity.
Asimadoline is a proprietary, peripherally restricted small molecule therapeutic initially discovered and developed by Merck KGaA of Darmstadt, Germany to treat peripheral pain. Tioga has acquired all rights to asimadoline from Merck. The compound has been tested in over 1,000 subjects to date and has demonstrated a promising safety profile. Asimadoline has shown encouraging clinical efficacy for the treatment of IBS and has the potential for treating other gastrointestinal diseases.